title: Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments.
abstract: Different pyrene-labeled phospholipid monolayer vesicles were used as substrates for the bovine milk lipoprotein lipase activity. The effects of synthetic fragments of apoprotein C II were measured on the hydrolysis of 1-myristoyl-2[9(1pyrenyl)-nonanoyl] phosphatidylcholine in vesicles: The activating capacity of fragments 30-78 and 43-78, 50-78 and 55-78, compared to entire apo CII, were similar to that obtained with hydrolysable triglycerides. Our study shows that the longer the carboxy terminal fragment is, the higher is the activation. The phospholipid hydrolysis activity represents in the presence of apo C II, 36% of the triglycerides hydrolysis activity. Phospholipid hydrolysis is less dependent on activator than triglycerides hydrolysis (100% and 300% of increase with apo CII for phosphatidyl-choline and triglycerides respectively). The ratio hydrolysis without apo C II/hydrolysis with apo CII was different when other phospholipids than myrystoyl-phospatidylcholine were assayed: phosphatidyl-serine, ethanolamine, -choline, -glycerol, or diglycerides and butanoylglycerols. Fragment CIII(1) (1-40) which did not bind to lipids, had no inhibitory effect. The entire sugar moiety and the first 40 amino acids are not required for the total inhibition of LPL. Inhibition was also obtained with Apo A I, A II,C I and fragments of apo E.
authors.affiliation: I.N.S.E.R.M. U. 308, Faculté de Médecine-BP 184-avenue de la Forêt de Haye 54505, Vandoeuvre Cèdex, France. lambert@u308.nancy.inserm.fr
authors.forename: D A
authors.initials: DA
authors.lastname: Lambert
authors.forename: L C
authors.initials: LC
authors.lastname: Smith
authors.forename: H
authors.initials: H
authors.lastname: Pownall
authors.forename: J T
authors.initials: JT
authors.lastname: Sparrow
authors.forename: J P
authors.initials: JP
authors.lastname: Nicolas
authors.forename: A M
authors.initials: AM
authors.lastname: Gotto
mesh_terms: D000818:Animals; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A / Q000494:pharmacology; D001056:Apolipoproteins C / Q000494:pharmacology; D001057:Apolipoproteins E / Q000494:pharmacology; D001059:Apoproteins / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D006868:Hydrolysis; D007700:Kinetics; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008892:Milk / Q000201:enzymology*; D010446:Peptide Fragments / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism*
chemical_list: D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D001059:Apoproteins; D010446:Peptide Fragments; D010743:Phospholipids; D008071:Lipoprotein Lipase